16:11 EST Cytokinetics (CYTK) sees FY24 GAAP operating expense $555M-$575M
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics reports Q3 EPS ($1.36), consensus ($1.25)
- Cytokinetics (CYTK) Q3 Earnings Cheat Sheet
- Cytokinetics to provide an update on cardiac myosin modulation programs
- Cytokinetics price target raised to $120 from $90 at H.C. Wainwright
- Cytokinetics presents additional data from SEQUOIA-HCM trial